Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

by Trotman, Judith , Treon, Steven P , Herbaux, Charles , Tam, Constantine , Li, Jianling , Orsucci, Lorella , Salman, Zeena , Buske, Christian , Macdonald, David , Tedeschi, Alessandra , García-Sanz, Ramón , Palomba, M. Lia , Mahe, Beatrice , Graef, Thorsten , Leblond, Veronique , Shustik, Chaim , Dimopoulos, Meletios A , Matous, Jeffrey V , Kastritis, Efstathios

in Adult / Aged / Aged, 80 and over / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Arthralgia / Atrial Fibrillation - chemically induced / B-cell lymphoma / Bone marrow / Cancer / CXCR4 protein / Diarrhea / Disease-Free Survival / Female / Fibrillation / Hemoglobin / Hemoglobins - analysis / Hemorrhage / Hospitals / Humans / Hypertension / Immunoglobulin M / Immunoglobulin M - blood / Immunotherapy / Infusions, Intravenous - adverse effects / Inhibitor drugs / Lymphocytes B / Macroglobulinemia / Male / Medical research / Middle Aged / Monoclonal antibodies / MyD88 protein / Nausea / Patients / Pyrazoles - administration & dosage / Pyrazoles - adverse effects / Pyrimidines - administration & dosage / Pyrimidines - adverse effects / R&D / Research & development / Response rates / Rituximab / Rituximab - administration & dosage / Rituximab - adverse effects / Survival Analysis / Targeted cancer therapy / Waldenstrom Macroglobulinemia - blood / Waldenstrom Macroglobulinemia - drug therapy

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

2018

Confirm

Do you wish to request the book?

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Trotman, Judith,

Treon, Steven P,

Herbaux, Charles,

Tam, Constantine,

Li, Jianling,

Orsucci, Lorella,

Salman, Zeena,

Buske, Christian,

Macdonald, David,

Tedeschi, Alessandra,

García-Sanz, Ramón,

Palomba, M. Lia,

Mahe, Beatrice,

Graef, Thorsten,

Leblond, Veronique,

Shustik, Chaim,

Dimopoulos, Meletios A,

Matous, Jeffrey V,

Kastritis, Efstathios

2018

Overview

A randomized trial comparing ibrutinib plus rituximab with rituximab alone in patients with Waldenström’s macroglobulinemia showed significantly higher rates of progression-free survival and overall response with the addition of ibrutinib.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Arthralgia

/ Atrial Fibrillation - chemically induced